C4 Therapeutics Q2 2026: Cash Runway Extended to 2028, Cemsidomide Timelines Updated
CCCC has more than doubled off its 52-week low of $1.69.
Summary
C4 Therapeutics' Q2 2026 filing reveals a cash runway through 2028, a narrowed net loss, and updated clinical timelines for cemsidomide, including Phase 2 data expected in H2 2027.
Key Events · Earnings and Guidance · CCCC
-
Cash Runway Extended to 2028
Cash, cash equivalents, and marketable securities totaled $300.4 million as of June 30, 2026, sufficient to fund operations through the end of 2028.
-
Net Loss Narrows
Net loss for the six months ended June 30, 2026 was $48.8 million, down from $52.3 million in the prior year period, driven by lower R&D and G&A expenses.
-
ATM Program Raises $33.5M
During Q2 2026, the company sold 9.3 million shares at an average price of $3.71 per share under its at-the-market program, generating net proceeds of $33.5 million.
-
Cemsidomide Clinical Timelines Updated
Phase 2 MOMENTUM enrollment completion expected Q1 2027 with initial data in H2 2027; Phase 1b cemsidomide + elranatamab dose escalation update expected H2 2026, data mid-2027.
Analysis · CCCC · Life Sciences
A strengthened balance sheet headlines C4 Therapeutics' Q2 2026 10-Q, with $300.4 million in cash and equivalents extending the runway through the end of 2028 — a critical survival metric for a clinical-stage biotech. The net loss narrowed to $48.8 million from $52.3 million a year ago, while the company raised $33.5 million through its ATM program at an average price of $3.71 per share. Updated clinical timelines for lead asset cemsidomide show Phase 2 MOMENTUM enrollment completion now expected in Q1 2027 and initial data in H2 2027. A new Phase 1b combination trial is planned for H1 2027. Reflecting capital prioritization, development of CFT8919 outside Greater China has been halted. These updates follow positive Phase 1 data presented in June 2026, reinforcing cemsidomide as the primary value driver.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1645 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CCCC was trading at $3.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $400.3M. The 52-week trading range was $1.69 to $5.17. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.